Janet M Shipley

List of Publications by Year
in descending order

150	19,318	41323	11928
papers	citations	49 h-index	134 g-index

157	157	157	23930
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.	13.7	9,374
2	Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genetics, 1994, 7, 502-508.	9.4	723
3	Rhabdomyosarcoma. Nature Reviews Disease Primers, 2019, 5, 1.	18.1	619
4	A census of amplified and overexpressed human cancer genes. Nature Reviews Cancer, 2010, 10, 59-64.	12.8	480
5	Fusion Geneâ€"Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma. Journal of Clinical Oncology, 2010, 28, 2151-2158.	0.8	426
6	Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Research, 2002, 62, 135-40.	0.4	390
7	Testicular germ-cell cancer. Lancet, The, 2006, 367, 754-765.	6.3	370
8	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 1997, 15, 2233-2239.	2.6	298
9	PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. Journal of Clinical Oncology, 2012, 30, 1670-1677.	0.8	297
10	Poorly Differentiated Synovial Sarcoma. American Journal of Surgical Pathology, 1999, 23, 106-112.	2.1	209
11	Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene. Cancer Research, 2006, 66, 290-302.	0.4	208
12	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nature Communications, 2015, 6, 5973.	5.8	161
13	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. Cancer Cell, 2014, 26, 273-287.	7.7	152
14	Amplification and Overexpression of the KIT Gene Is Associated with Progression in the Seminoma Subtype of Testicular Germ Cell Tumors of Adolescents and Adults. Cancer Research, 2005, 65, 8085-8089.	0.4	149
15	Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nature Genetics, 2013, 45, 686-689.	9.4	149
16	Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes and Cancer, 1999, 26, 275-285.	1.5	145
17	DYRK1A-Dosage Imbalance Perturbs NRSF/REST Levels, Deregulating Pluripotency and Embryonic Stem Cell Fate in Down Syndrome. American Journal of Human Genetics, 2008, 83, 388-400.	2.6	139
18	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 19, 1061-1071.	5.1	137

#	Article	IF	Citations
19	Gain of 1q Is Associated with Adverse Outcome in Favorable Histology Wilmsâ€™ Tumors. American Journal of Pathology, 2001, 158, 393-398.	1.9	127
20	Role of gain of 12p in germ cell tumour development. Apmis, 2003, 111, 161-173.	0.9	126
21	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo. Clinical Cancer Research, 2013, 19, 5940-5951.	3.2	124
22	Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nature Genetics, 2017, 49, 1133-1140.	9.4	120
23	Distinct roles for miRâ€1 and miRâ€133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB Journal, 2010, 24, 3427-3437.	0.2	118
24	Relationship Between MYCN Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype. Journal of Clinical Oncology, 2005, 23, 880-888.	0.8	106
25	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Journal of Clinical Oncology, 2021, 39, 2859-2871.	0.8	101
26	Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development. Genes Chromosomes and Cancer, 2009, 48, 455-467.	1.5	98
27	Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma. Cancer Research, 2007, 67, 57-65.	0.4	94
28	The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers. American Journal of Pathology, 2010, 176, 2607-2615.	1.9	89
29	Testicular germ cell tumours: predisposition genes and the male germ cell niche. Nature Reviews Cancer, 2011, 11, 278-288.	12.8	86
30	Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget, 2017, 8, 71371-71384.	0.8	85
31	Distinct Effects of Ligand-Induced PDGFRÎ± and PDGFRÎ² Signaling in the Human Rhabdomyosarcoma Tumor Cell and Stroma Cell Compartments. Cancer Research, 2013, 73, 2139-2149.	0.4	83
32	The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. Nature Reviews Urology, 2016, 13, 409-419.	1.9	83
33	8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 1388-1409.	2.9	83
34	Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer, 2006, 54, 155-162.	0.9	78
35	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. , 2000, 28, 220-226.		75
36	Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. Journal of Pathology, 2009, 217, 94-102.	2.1	74

#	Article	IF	Citations
37	Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy. Clinical Cancer Research, 2012, 18, 796-807.	3.2	74
38	A Gene Expression Signature Associated with Metastatic Outcome in Human Leiomyosarcomas. Cancer Research, 2004, 64, 7201-7204.	0.4	73
39	Activating Mutations and/or Expression Levels of Tyrosine Kinase Receptors GRB7, RAS, and BRAF in Testicular Germ Cell Tumors. Neoplasia, 2005, 7, 1047-1052.	2.3	70
40	Characterization of chromosome 1 abnormalities in malignant melanomas. , 2000, 28, 121-125.		69
41	REVIEW ARTICLE. THE MOLECULAR PATHOLOGY OF SMALL ROUND-CELL TUMOURSâ€"RELEVANCE TO DIAGNOSIS, PROGNOSIS, AND CLASSIFICATION. , 1996, 178, 116-121.		68
42	Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes and Cancer, 2002, 34, 104-114.	1.5	66
43	Identification and cDNA Cloning of a Novel Mammalian C2 Domain-Containing Phosphoinositide 3-Kinase, HsC2-PI3K. Biochemical and Biophysical Research Communications, 1997, 233, 537-544.	1.0	64
44	Rhabdomyosarcoma: Current Challenges and Their Implications for Developing Therapies. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a025650-a025650.	2.9	60
45	Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence. Genes Chromosomes and Cancer, 1997, 20, 275-281.	1.5	59
46	cDNA Cloning of a Third Human C2-Domain-Containing Class II Phosphoinositide 3-Kinase, PI3K-C2Î³, and Chromosomal Assignment of This Gene (PIK3C2G) to 12p12. Genomics, 1998, 54, 569-574.	1.3	57
47	Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet, The, 2002, 360, 385-386.	6.3	57
48	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood and Cancer, 2019, 66, e27869.	0.8	57
49	Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). British Journal of Haematology, 2006, 133, 35-42.	1.2	56
50	Primitive Neuroectodermal Tumor of the Kidney Confirmed by Fluorescence In Situ Hybridization. American Journal of Surgical Pathology, 1997, 21, 461-468.	2.1	56
51	Dual colour fluorescencein situ hybridization to paraffin-embedded samples to deduce the presence of the der(X)t(X;18)(p11.2;q11.2) and involvement of either theSSX1 orSSX2 gene: a diagnostic and prognostic aid for synovial sarcoma. , 1999, 187, 490-496.		55
52	Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis. Genes Chromosomes and Cancer, 2001, 31, 54-64.	1.5	55
53	Clinical relevance of molecular genetics to paediatric sarcomas. Journal of Clinical Pathology, 2007, 60, 1187-1194.	1.0	52
54	Fusion status in patients with lymph nodeâ€positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer, 2018, 124, 3201-3209.	2.0	51

#	Article	IF	Citations
55	Novel formation and amplification of thePAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. , 1996, 17, 7-13.		50
56	Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma. Genes Chromosomes and Cancer, 2006, 45, 839-845.	1.5	50
57	Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nature Protocols, 2008, 3, 220-234.	5.5	50
58	Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults. Genes Chromosomes and Cancer, 2008, 47, 547-557.	1.5	48
59	Vgll3 operates via Tead1, Tead3 and Tead4 to influence myogenesis in skeletal muscle. Journal of Cell Science, 2019, 132, .	1.2	48
60	Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives. Sarcoma, 2011, 2011, 1-11.	0.7	45
61	INTERPHASE FLUORESCENCEIN SITU HYBRIDIZATION DETECTION OF t(2;13)(q35;q14) IN ALVEOLAR RHABDOMYOSARCOMAâ€"A DIAGNOSTIC TOOL IN MINIMALLY INVASIVE BIOPSIES. , 1996, 178, 410-414.		44
62	Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk. Oncogene, 1997, 15, 1497-1502.	2.6	44
63	Identification of ZDHHC14 as a novel human tumour suppressor gene. Journal of Pathology, 2014, 232, 566-577.	2.1	44
64	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European Journal of Cancer, 2019, 121, 224-235.	1.3	44
65	ATR Is a Therapeutic Target in Synovial Sarcoma. Cancer Research, 2017, 77, 7014-7026.	0.4	43
66	Genomic landscape of platinum resistant and sensitive testicular cancers. Nature Communications, 2020, 11, 2189.	5.8	43
67	The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. Oncogene, 2002, 21, 5791-5796.	2.6	42
68	Diagnosis of Ewing's sarcoma and related tumours by detection of chromosome 22q12 translocations using fluorescencein situ hybridization on tumour touch imprints. Journal of Pathology, 1995, 176, 137-142.	2.1	40
69	The Hippo effector <scp>TAZ</scp> (<scp>WWTR1</scp>) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma. Journal of Pathology, 2016, 240, 3-14.	2.1	40
70	Establishing Germ Cell Origin of Undifferentiated Tumors by Identifying Gain of 12p Material Using Comparative Genomic Hybridization Analysis of Paraffin-Embedded Samples. Diagnostic Molecular Pathology, 1998, 7, 260-266.	2.1	39
71	Mediastinal synovial sarcoma: report of two cases with molecular genetic analysis. Annals of Thoracic Surgery, 2002, 73, 628-630.	0.7	39
72	Comparative genomic hybridization and BUB1B mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome. Cancer Letters, 2006, 239, 234-238.	3.2	39

#	Article	IF	Citations
73	Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene, 2004, 23, 9142-9147.	2.6	38
74	The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors, 2006, 24, 197-208.	0.5	38
75	Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer, 2021, 68, e28798.	0.8	38
76	Identification of four new susceptibility loci for testicular germ cell tumour. Nature Communications, 2015, 6, 8690.	5.8	36
77	Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. Cancer Genetics and Cytogenetics, 2003, 140, 73-77.	1.0	35
78	Synovial sarcoma specific translocation associated with both epithelial and spindle cell components. , 1999, 82, 605-608.		32
79	Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response. Cancer Research, 2021, 81, 1667-1680.	0.4	32
80	Unusual case of leukemic mantle cell lymphoma with amplifiedCCND1/IGH fusion gene. Genes Chromosomes and Cancer, 2002, 33, 206-212.	1.5	31
81	Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. Cancer Research, 2020, 80, 832-842.	0.4	31
82	Chromosome 3 imbalances are the most frequent aberration found in non-small cell lung carcinoma. Lung Cancer, 1999, 23, 61-66.	0.9	30
83	MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. Cancer Letters, 2017, 385, 251-260.	3.2	30
84	Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp andSTK11-negative PJS cases. Genes Chromosomes and Cancer, 2004, 41, 163-169.	1.5	29
85	Cloning and Mapping of Members of the MYM Family. Genomics, 1999, 60, 244-247.	1.3	28
86	Hypoxia and its therapeutic possibilities in paediatric cancers. British Journal of Cancer, 2021, 124, 539-551.	2.9	28
87	Loss of 13q14-q21 and Gain of 5p14-pter in the Progression of Leiomyosarcoma. Modern Pathology, 2003, 16, 778-785.	2.9	27
88	Oncocytic Adrenal Cortical Carcinosarcoma With Pleomorphic Rhabdomyosarcomatous Metastases. American Journal of Surgical Pathology, 2012, 36, 470-477.	2.1	26
89	Definition of chromosome aberrations in testicular germ cell tumor cell lines by 24-color karyotyping and complementary molecular cytogenetic analyses. Cancer Genetics and Cytogenetics, 2001, 128, 120-129.	1.0	25
90	The pattern of genomic gains in salivary gland MALT lymphomas. Haematologica, 2007, 92, 921-927.	1.7	25

#	Article	IF	Citations
91	The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells. BMC Cancer, 2018, 18, 217.	1.1	25
92	Ageâ€related biological features of germ cell tumors. Genes Chromosomes and Cancer, 2014, 53, 215-227.	1.5	24
93	IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. Journal of Pathology, 2018, 244, 242-253.	2.1	24
94	Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. Clinical Cancer Research, 2016, 22, 1265-1273.	3.2	23
95	Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. British Journal of Cancer, 2016, 115, 473-479.	2.9	23
96	Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines. Genes Chromosomes and Cancer, 2005, 43, 211-216.	1.5	22
97	Epigenetic Targets in Synovial Sarcoma: A Mini-Review. Frontiers in Oncology, 2019, 9, 1078.	1.3	22
98	Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes Chromosomes and Cancer, 2011, 50, 186-195.	1.5	21
99	Clinical Application of Prognostic Gene Expression Signature in Fusion Geneâ€“Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2015, 21, 4733-4739.	3.2	21
100	Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials. Pediatric Blood and Cancer, 2017, 64, e26386.	0.8	21
101	Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) â€“ RMS2005 study. European Journal of Cancer, 2021, 151, 84-93.	1.3	21
102	No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. Cancer Letters, 2006, 235, 136-140.	3.2	20
103	Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. Pediatric Blood and Cancer, 2019, 66, e27888.	0.8	19
104	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. European Journal of Cancer, 2022, 172, 367-386.	1.3	19
105	Evaluation of 24-color multifluor-fluorescence in-situ hybridization (M-FISH) karyotyping by comparison with reverse chromosome painting of the human breast cancer cell line T-47D. Chromosome Research, 2000, 8, 127-132.	1.0	18
106	Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior. Genes Chromosomes and Cancer, 2003, 38, 207-214.	1.5	18
107	Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas. Journal of Clinical Pathology, 2011, 64, 587-591.	1.0	18
108	An additional human chromosome 21 causes suppression of neural fate of pluripotent mouse embryonic stem cells in a teratoma model. BMC Developmental Biology, 2007, 7, 131.	2.1	17

#	Article	IF	Citations
109	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	0.8	16
110	Loss of the chromosomal region 5q11-q31 in the myeloid cell line HL-60: Characterization by comparative genomic hybridization and fluorescence in situ hybridization. , 1996, 15, 182-186.		14
111	Characterization of a t(8;13)(p11;q11-12) in an atypical myeloproliferative disorder. Genes Chromosomes and Cancer, 1998, 21, 70-73.	1.5	14
112	Disruption of the ATM gene in breast cancer. Cancer Genetics and Cytogenetics, 2001, 126, 97-101.	1.0	14
113	Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. Genes Chromosomes and Cancer, 2005, 43, 315-328.	1.5	14
114	Association between Large-scale Genomic Homozygosity without Chromosomal Loss and Nonseminomatous Germ Cell Tumor Development. Cancer Research, 2005, 65, 9137-9141.	0.4	14
115	Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2. Cellular Signalling, 2010, 22, 357-365.	1.7	14
116	Fluorescence In Situ Hybridization Analysis of Formalin Fixed Paraffin Embedded Tissues, Including Tissue Microarrays. Methods in Molecular Biology, 2010, 659, 51-70.	0.4	13
117	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Scientific Reports, 2018, 8, 10614.	1.6	13
118	Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1659-1670.	1.2	13
119	The molecular biology of soft tissue sarcomas. European Journal of Cancer, 1993, 29, 2054-2058.	1.3	12
120	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas. Frontiers in Oncology, 2019, 9, 1271.	1.3	12
121	Desmoplastic small round cell tumor (DSRCT): emerging therapeutic targets and future directions for potential therapies. Expert Opinion on Therapeutic Targets, 2020, 24, 281-285.	1.5	11
122	Characterisation of a human serine hydroxymethyltransferase pseudogene and its localisation to 1p32.3â€“33. Human Genetics, 1996, 97, 340-344.	1.8	10
123	Polygenic susceptibility to testicular cancer: implications for personalised health care. British Journal of Cancer, 2015, 113, 1512-1518.	2.9	10
124	Chromosome translocations in sarcomas and the analysis of paraffin-embedded material. , 1998, 184, 1-3.		9
125	Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. Pediatric Blood and Cancer, 2006, 46, 820-824.	0.8	9
126	HES6 enhances the motility of alveolar rhabdomyosarcoma cells. Experimental Cell Research, 2013, 319, 103-112.	1.2	9

#	Article	IF	Citations
127	Targeted resequencing of pediatric rhabdomyosarcoma: report from the Childrenâ€™s Oncology Group, the Childrenâ€™s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.. Journal of Clinical Oncology, 2018, 36, 10515-10515.	0.8	9
128	Characterization of a t(10; 11) (p13-14; q14-21) in the monoblastic cell line U937. Genes Chromosomes and Cancer, 1995, 13, 138-142.	1.5	8
129	Recent advances in the diagnosis, prognosis and classification of childhood solid tumours. British Medical Bulletin, 1996, 52, 724-741.	2.7	7
130	Putting the colours into chromogenicin situ hybridization (CISH). Journal of Pathology, 2006, 210, 1-2.	2.1	7
131	Fluorescence In Situ Hybridization for Cancer-Related Studies. Methods in Molecular Biology, 2012, 878, 149-174.	0.4	7
132	FGF7â€“FGFR2 autocrine signaling increases growth and chemoresistance of fusionâ€positive rhabdomyosarcomas. Molecular Oncology, 2022, 16, 1272-1289.	2.1	7
133	No evidence for V600E BRAF mutation in the seminoma cell line TCam-2. Genes Chromosomes and Cancer, 2010, 49, 963-966.	1.5	6
134	Genome-wide methylation analysis identifies genes silenced in non-seminoma cell lines. Npj Genomic Medicine, 2016, 1, 15009.	1.7	6
135	Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A. Cancers, 2021, 13, 1734.	1.7	6
136	Subtle genomic alterations and genomic instability revealed in diploid cancer cell lines. Cancer Letters, 2008, 267, 49-54.	3.2	4
137	Reply to S. Stegmaier et al. Journal of Clinical Oncology, 2012, 30, 4040-4041.	0.8	4
138	Fusion gene addiction: can tumours be forced to give up the habit?. Journal of Pathology, 2017, 242, 263-266.	2.1	4
139	Prediction of relapse in stage I nonseminomatous germ cell tumors (NSGCT) by CXCL12: Results from the MRC TE08 and TE22 clinical trials.. Journal of Clinical Oncology, 2013, 31, 319-319.	0.8	4
140	Inconvenience of Convenience Cohortsâ€”Letter. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1388-1388.	1.1	3
141	Reply to J.R. Anderson et al. Journal of Clinical Oncology, 2010, 28, e589-e590.	0.8	2
142	Immunohistochemical Detection of Glypican-5 in Paraffin-embedded Material. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 189-195.	0.6	2
143	INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION DETECTION OF t(2;13)(q35;q14) IN ALVEOLAR RHABDOMYOSARCOMAâ€”A DIAGNOSTIC TOOL IN MINIMALLY INVASIVE BIOPSIES. Journal of Pathology, 1996, 178, 410-414.	2.1	2
144	Abstract 2986: Meta-analysis of whole exome sequencing data reveals the mutational spectrum of testicular germ cell tumors. , 2015, , .		1

#	Article	IF	Citations
145	Less Can Be More for Gene Dose and Drug Sensitivity. Clinical Cancer Research, 2015, 21, 4750-4752.	3.2	0
146	Abstract 5343: Aberrant activation of hedgehog signaling confers a poor prognosis in embryonal and fusion gene negative alveolar rhabdomyosarcoma. , 2011, , .		0
147	Molecular biomarkers of risk in rare and other cancers â€“ identification and impact. Biochemist, 2016, 38, 10-13.	0.2	0
148	Abstract 2975: Synthetic lethality in synovial sarcoma: SS18-SSX fusions and DNA damage response (DDR) inhibitors. , 2018, , .		0
149	Experimental Models. Pediatric Oncology, 2021, , 129-147.	0.5	0
150	Characterisation of a human serine hydroxymethyltransferase pseudogene and its localisation to 1p32.3-33. Human Genetics, 1996, 97, 340-344.	1.8	0